The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination?
Open accessAbstract
Peptide vaccines incorporate one or more short or long amino acid sequences as tumor antigens, combined with a vaccine adjuvant. Thus, they fall broadly into the category of defined antigen vaccines, along with vaccines using protein, protein subunits, DNA, or RNA. They remain one of the most immunogenic approaches, based on measures of T-cell response in the blood or in draining lymph nodes. However, existing peptide vaccines have had limited success at inducing clinical tumor regressions, despite reliable induction of T-cell responses. Several new developments offer promise for improving peptide vaccines, including use of long peptides, optimization of adjuvants including toll-like receptor agonists, and combination with systemic therapies that may reduce tumor-associated immune dysfunction, such as blockade of PD-1/PD-L1 interactions. To apply these new approaches optimally, it will be critical to study their effects in the context of defined antigens, for which peptide vaccines are optimal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., & Slingluff, C. L. (1994) · Science · doi:10.1126/science.7513441 · Cited by 824
Self-citationHigano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., Provost, N., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 810
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function
Peng, G., Guo, Z., Kiniwa, Y., Voo, K. S., Peng, W., Fu, T., Wang, D. Y., Li, Y., Wang, H. Y., & Wang, R.-F. (2005) · Science · doi:10.1126/science.1113401 · Cited by 746
Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., & Pardoll, D. M. (1991) · Science · doi:10.1126/science.1948050 · Cited by 719
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523373 · Cited by 640
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 465
Knutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Liénard, D., Lejeune, F., Rimoldi, D., Guillaume, P., Meidenbauer, N., Mackensen, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3066 · Cited by 361
The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355
Lichterfeld, M., Kaufmann, D. E., Yu, X. G., Mui, S. K., Addo, M. M., Johnston, M. N., Cohen, D., Robbins, G. K., Pae, E., Alter, G., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041270 · Cited by 339
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
Fife, B. T., Guleria, I., Gubbels Bupp, M., Eagar, T. N., Tang, Q., Bour-Jordan, H., Yagita, H., Azuma, M., Sayegh, M. H., & Bluestone, J. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061577 · Cited by 325
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J., & Melief, C. J. M. (1989) · Cell · doi:10.1016/0092-8674(89)90006-8 · Cited by 301
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., & Kast, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7855 · Cited by 292
Loré, K., Betts, M. R., Brenchley, J. M., Kuruppu, J., Khojasteh, S., Perfetto, S., Roederer, M., Seder, R. A., & Koup, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4320 · Cited by 291
Bennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
Topalian, S. L., Gonzales, M. I., Parkhurst, M., Li, Y. F., Southwood, S., Sette, A., Rosenberg, S. A., & Robbins, P. F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.5.1965 · Cited by 257
Principles for Adoptive T Cell Therapy of Human Viral Diseases
Riddell, S. R. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.545 · Cited by 248
Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes
Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M. M., Boon, T., & van der Bruggen, P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.767 · Cited by 234
Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., van der Burg, S. H., & Offringa, R. (2008) · European Journal of Immunology · doi:10.1002/eji.200737995 · Cited by 229
Slingluff, C. L., Yamshchikov, G. V., Neese, P. Y., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D. J., Deacon, D. H., Hibbitts, S., Grosh, W. W., et al. (2001) · PubMed · Cited by 229
Self-citationDarrow, T. L., Slingluff, C. L., & Seigler, H. F. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.9.3329 · Cited by 214
Self-citationToes, R. E., Blom, R. J., Offringa, R., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3911 · Cited by 208
Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M. J., Koganty, R. R., Longenecker, B. M., Yao, T. J., Oettgen, H. F., & Po, L. (1995) · PubMed · Cited by 206
Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results
Cluff, C. W. (2009) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-1603-7_10 · Cited by 205
Zhu, Q., Egelston, C., Gagnon, S., Sui, Y., Belyakov, I. M., Klinman, D. M., & Berzofsky, J. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39293 · Cited by 186
Slingluff, C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Ross, M. I., Haas, N. B., Grosh, W. W., Boisvert, M. E., Kirkwood, J. M., & Chianese-Bullock, K. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1544 · Cited by 171
Self-citationMäkelä, S. M., Strengell, M., Pietilä, T. E., Österlund, P., & Julkunen, I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808503 · Cited by 167
Slingluff, C. L., Petroni, G. R., Chianese-Bullock, K. A., Smolkin, M. E., Hibbitts, S., Murphy, C., Johansen, N., Grosh, W. W., Yamshchikov, G. V., Neese, P. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0486 · Cited by 163
Self-citationZarour, H. M., Kirkwood, J. M., Kierstead, L. S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.400 · Cited by 157
Mohammed, F., Cobbold, M., Zarling, A. L., Salim, M., Barrett-Wilt, G. A., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., & Willcox, B. E. (2008) · Nature Immunology · doi:10.1038/ni.1660 · Cited by 155
Slingluff, C. L., Petroni, G. R., Yamshchikov, G. V., Hibbitts, S., Grosh, W. W., Chianese‐Bullock, K. A., Bissonette, E. A., Barnd, D. L., Deacon, D. H., Patterson, J. W., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.212 · Cited by 145
Self-citationLawson, D. H., Lee, S., Zhao, F., Tarhini, A. A., Margolin, K. A., Ernstoff, M. S., Atkins, M. B., Cohen, G. I., Whiteside, T. L., Butterfield, L. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0500 · Cited by 141
Delineation of several DR-restricted tetanus toxin T cell epitopes.
Demotz, S., Lanzavecchia, A., Eisel, U. L. M., Niemann, H., Widmann, C., & Corradin, G. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.2.394 · Cited by 139
Slingluff, C. L., Petroni, G. R., Chianese‐Bullock, K. A., Smolkin, M. E., Ross, M. I., Haas, N. B., von Mehren, M., & Grosh, W. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8053 · Cited by 129
Self-citationHirata, S., Senju, S., Matsuyoshi, H., Fukuma, D., Uemura, Y., & Nishimura, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.1888 · Cited by 127
Chianese‐Bullock, K. A., Pressley, J., Garbee, C. F., Hibbitts, S., Murphy, C., Yamshchikov, G. V., Petroni, G. R., Bissonette, E. A., Neese, P. Y., Grosh, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3080 · Cited by 126
Self-citationSlingluff, C. L., Petroni, G. R., Olson, W. C., Czarkowski, A. R., Grosh, W. W., Smolkin, M. E., Chianese‐Bullock, K. A., Neese, P. Y., Deacon, D. H., Nail, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3161 · Cited by 119
Self-citationDepontieu, F., Qian, J., Zarling, A. L., McMiller, T. L., Salay, T. M., Norris, A., English, A. M., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903852106 · Cited by 117
Phan, G. Q., Touloukian, C. E., Yang, J. C.-H., Restifo, N. P., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Seipp, C. A., Rogers-Freezer, L. J., et al. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00007 · Cited by 114
Monophosphoryl lipid A (MPL®)* promotes allergen‐induced immune deviation in favour of Th1 responses
Puggioni, F., Durham, S. R., & Francis, J. N. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00762.x · Cited by 107
Slingluff, C. L., Colella, T. A., Thompson, L. W., et al. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050015 · Cited by 95
Self-citationZhu, X., Fallert-Junecko, B., Fujita, M., Ueda, R., Kohanbash, G., Kastenhuber, E. R., McDonald, H. A., Liu, Y., Kaliński, P., Reinhart, T. A., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0876-3 · Cited by 95
Matsui, S., Ahlers, J. D., Vortmeyer, A. O., Terabe, M., Tsukui, T., Carbone, D. P., Liotta, L. A., & Berzofsky, J. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.184 · Cited by 92
Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M., & Morton, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1540 · Cited by 91
Ahonen, C. L., Wasiuk, A., Fuse, S., Turk, M. J., Ernstoff, M. S., Suriawinata, A. A., Gorham, J. D., Kedl, R. M., Usherwood, E. J., & Noelle, R. J. (2008) · Blood · doi:10.1182/blood-2007-09-114371 · Cited by 86
Sznol, M., Powderly, J. D., Smith, D. C., Brahmer, J. R., Drake, C. G., McDermott, D. F., Lawrence, D. P., Wolchok, J. D., Topalian, S. L., & Lowy, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2506 · Cited by 85
Halder, T. M., Pawelec, G., Kirkin, A. F., Zeuthen, J., Meyer, H. E., Kun, L., & Kalbacher, H. (1997) · PubMed · Cited by 84
Schwartzentruber, D. J., Lawson, D. J., Richards, J. M., Conry, R. M., Miller, D. M., Triesman, J., Gailani, F., Riley, L., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra9011 · Cited by 83
Hamid, O., Solomon, J. C., Scotland, R., Garcia, M., Sian, S., Ye, W., Groshen, S. L., & Weber, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1450 · Cited by 82
Scheibenbogen, C., Schadendorf, D., Bechrakis, N. E., Nagorsen, D., Hofmann, U., Servetopoulou, F., Letsch, A., Philipp, A., Foerster, M. H., Schmittel, A. H., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10961 · Cited by 80
Li, K., Adibzadeh, M., Halder, T. M., Kalbacher, H., Heinzel, S., Müller, C. A., Zeuthen, J., & Pawelec, G. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050501 · Cited by 79
CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects
Slezak, S. L., Bettinotti, M. P., Selleri, S., Adams, S. D., Marincola, F. M., & Stroncek, D. F. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-17 · Cited by 72
Powell, D. J., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200401000-00004 · Cited by 71
Immunity to Melanoma Antigens: From Self‐Tolerance to Immunotherapy
Slingluff, C. L., Chianese‐Bullock, K. A., Bullock, T. N. J., Grosh, W. W., Mullins, D. W., Nichols, L. A., Olson, W. C., Petroni, G. R., Smolkin, M. E., & Engelhard, V. H. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90007-8 · Cited by 63
Self-citationKhong, H. T., Yang, J. C.-H., Topalian, S. L., Sherry, R. M., Mavroukakis, S. A., White, D. E., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00007 · Cited by 55
Speiser, D. E., Pittet, M. J., Rimoldi, D., Guillaume, P., Luescher, I. F., Líénard, D., Lejeune, F. J., Cerottini, J., & Romero, P. J. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.010 · Cited by 54
Schaefer, J. T., Patterson, J. W., Deacon, D. H., Smolkin, M. E., Petroni, G. R., Jackson, E. M., & Slingluff, C. L. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-79 · Cited by 49
Self-citationWong, R. M. H., Lau, R., Chang, J. R., Kuus-Reichel, T., Brichard, V. G., Bruck, C., & Weber, J. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0241 · Cited by 49
Ex vivoDetectable Human CD8 T-Cell Responses to Cancer-Testis Antigens
Baumgaertner, P., Rufer, N., Devêvre, E., Derré, L., Rimoldi, D., Geldhof, C., Voelter, V., Líénard, D., Romero, P. J., & Speiser, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3793 · Cited by 47
Li, Y., Depontieu, F., Sidney, J., Salay, T. M., Engelhard, V. H., Hunt, D. F., Sette, A., Topalian, S. L., & Mariuzza, R. A. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.037 · Cited by 46
Chianese‐Bullock, K. A., Lewis, S. T., Sherman, N. E., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.018 · Cited by 27
Rosenberg, S. A., Yang, J. C.-H., Kammula, U. S., Hughes, M. S., Restifo, N. P., Schwarz, S. L., Morton, K. E., Laurençot, C. M., & Sherry, R. M. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dac9de · Cited by 27
Slingluff, C. L., Petroni, G. R., Smolkin, M. E., Chianese‐Bullock, K. A., Smith, K. T., Murphy, C., Galeassi, N., Neese, P. Y., Grosh, W. W., Nail, C. J., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e311ac · Cited by 25
Self-citationMullins, D. W., & Engelhard, V. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4535 · Cited by 22
Na, I., Keilholz, U., Letsch, A., Bauer, S., Asemissen, A. M., Nagorsen, D., Thiel, E., & Scheibenbogen, C. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0198-7 · Cited by 14
Cited by
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., et al. (2017) · Advanced Materials · doi:10.1002/adma.201703969 · Cited by 501
Patente, T. A., Pinho, M. P., Oliveira, A. A., Evangelista, G. C. M., Bergami-Santos, P. C., & Barbuto, J. A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03176 · Cited by 392
Targeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 285
Metadata
- Authors
- Slingluff, C. L.
- Venue
- The Cancer Journal
- Published
- 2011-09
- Volume
- 17
- Issue
- 5
- Pages
- 343-350
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W1966916002
- Cited by
- 299
- References
- 82
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.